A prospective, single-arm study to evaluate the effect of repeated low-level red-light therapy on choroidal thickness in patients with high myopia with diffuse atrophy.

Ohno Kyoko0 个研究点目标入组 30 人开始时间: 2023年6月1日最近更新: 2024年4月1日

适应症

试验速览

暂无简介。

•(1) Provision of consent.
•(2) Age. 18 years or older.
•(3) Patients with either peripapillary diffuse atrophy
•(PDCA) or macular diffuse choroidal atrophy (MDCA), which are early findings of myopic maculopathy, in both or one eye on color fundus photographs.Posterior staphyloma with or without.
•(4) High myopia. sphere is less than -6.00D.
•(5) Patients with a central foveal choroidal thickness(SFCT) of 50um or greater in eyes with early findings of myopic maculopathy.
•(6) Willing and able to participate in all required of the study.

•(1) Secondary myopia, such as a history of retinopathy of prematurity or neonatal problems, o r syndromic myopia with a known genetic disease or connective tissue disorders, such as Stickler or Marfan syndrome.
•(2) Patients with retinitis pigmentosa-related diseases or other retinal hereditary diseases in the family.
•(3) Patients with night blindness.
•(4) Strabismus and binocular vision abnormalities in either eye.
•(5) Previous any intraocular surgery affecting refractive status.
•(6) Patients who have received low-dose atropine eye drops, orthokeratology, or progressive multifocal frame myopia progression control treatment in the past year.
•(7) Patients with myopic maculopathy plus lesions (myopic choroidal neovascularization, Fuchs spots, Lc).
•(8) Patients with systemic diseases (cardiac, respiratory, etc.).
•(9) Other reasons, including but not limited to ocular or other systemic abnormalities, that the physician may consider inappropriate for enrolment.

发起方

Ohno Kyoko